PXSQuarterly Report to Shareholders |
25/01/11 | | | Share |
|
PXSEU Bronchitol Marketing Application Update |
25/01/11 | PRICE SENSITIVE | | Share |
|
PXSAppendix 3B - Grant of Employee Options |
25/01/11 | | | Share |
|
PXSQuarterly Investor Report and Conference Call |
24/01/11 | | | Share |
|
PXSDisclosure notice under section 708A(5) of Corporations Act |
19/01/11 | | | Share |
|
PXSAppendix 3B |
19/01/11 | | | Share |
|
PXSBecoming a substantial holder |
14/01/11 | | | Share |
|
PXSAppendix 3B - Exercise of Employee Options |
12/01/11 | | | Share |
|
PXSAppendix 3B - Exercise of Employee Options |
21/12/10 | | | Share |
|
PXSShare Trading Policy |
21/12/10 | | | Share |
|
PXSBronchitol EU Marketing Authorisation Update |
20/12/10 | PRICE SENSITIVE | | Share |
|
PXSExtended Benefit with Bronchitol in Second PhaseIII CF Trial |
16/12/10 | PRICE SENSITIVE | | Share |
|
PXSPharmaxis Holds Pre-NDA Meeting with FDA for Bronchitol |
15/12/10 | | | Share |
|
PXSCeasing to be a substantial holder |
14/12/10 | | | Share |
|
PXSBronchitol Recommended for Approval by Australian Advisory C |
13/12/10 | PRICE SENSITIVE | | Share |
|
PXSPhase II Trial of ASM8 in Asthma Commences |
07/12/10 | PRICE SENSITIVE | | Share |
|
PXSAppendix 3B - Exercise of Employee Options |
30/11/10 | | | Share |
|
PXSAppendix 3B - Exercise of Employee Options |
25/11/10 | | | Share |
|
PXSChange of Director's Interest Notice |
25/11/10 | | | Share |
|
PXSAppendix 3B Exercise of Employee Options |
16/11/10 | | | Share |
|
PXSAppendix 3B - Grant of Employee Performance Rights |
15/11/10 | | | Share |
|
PXSUpdated Investor Presentation |
09/11/10 | | | Share |
|
PXSAppendix 3B - Exercise of Employee Options |
08/11/10 | | | Share |
|
PXSAPpendix 3B - Exercise of Employee Options |
02/11/10 | | | Share |
|
PXSAppendix 3B - Exercise of Employee Options |
28/10/10 | | | Share |
|
PXSAppendix 3B - Exercise of Employee Options |
22/10/10 | | | Share |
|
PXSPharmaxis Announces Positive Combined Phase 3 CF Results |
22/10/10 | PRICE SENSITIVE | | Share |
|
PXSBecoming a substantial holder |
21/10/10 | | | Share |
|
PXSChange of Director's Interest Notice |
20/10/10 | | | Share |
|
PXSResults of Meeting |
20/10/10 | | | Share |
|
PXSAppendix 3B - Option Issue |
20/10/10 | | | Share |
|
PXSCEO Presentation to 2010 AGM |
20/10/10 | | | Share |
|
PXSChairman's Address to 2010 AGM |
20/10/10 | | | Share |
|
PXSPharmaxis CEO Resumes Office |
20/10/10 | | | Share |
|
PXSAppendix 4C - quarterly |
13/10/10 | PRICE SENSITIVE | | Share |
|
PXSQuarterly Report to Shareholders |
13/10/10 | | | Share |
|
PXSQuarterly Investor Conference Call |
12/10/10 | | | Share |
|
PXSBecoming a substantial holder |
12/10/10 | | | Share |
|
PXSUS FDA APPROVES ARIDOL |
06/10/10 | PRICE SENSITIVE | | Share |
|
PXSAppendix 3B - grant of employee equity |
27/09/10 | | | Share |
|
PXSNotice of 2010 Annual General Meeting/Proxy Form |
10/09/10 | | | Share |
|
PXSPharmaxis 2010 Annual Review |
10/09/10 | | | Share |
|
PXSStatutory Annual Report |
10/09/10 | | | Share |
|
PXSProposed issue of options to CEO |
08/09/10 | | | Share |
|
PXSAppendix 3B - annual grant of employee options |
08/09/10 | | | Share |
|
PXSAgreement for European Marketing of Bronchitol |
31/08/10 | PRICE SENSITIVE | | Share |
|
PXSExercise of Employee Options |
27/07/10 | | | Share |
|
PXSQuarterly Report to Shareholders - June 2010 |
21/07/10 | | | Share |
|
PXSAppendix 4C - quarterly |
21/07/10 | PRICE SENSITIVE | | Share |
|
PXSQuarterly Investor Conference Call Details |
20/07/10 | | | Share |
|
PXSUpdate on Pharmaxis CEO |
08/07/10 | | | Share |
|
PXSCeasing to be a substantial holder |
25/06/10 | | | Share |
|
PXSUpdated Investor Presentation |
24/06/10 | | | Share |
|
PXSResults for Second Phase 3 Trial of Bronchitol in CF |
22/06/10 | PRICE SENSITIVE | | Share |
|
PXSInvestor Conference Call - Clinical Trial Results |
22/06/10 | | | Share |
|
PXSTrading Halt |
21/06/10 | PRICE SENSITIVE | | Share |
|
PXSPharmaxis CEO |
18/06/10 | | | Share |
|
PXSExercise of Employee Options |
31/05/10 | | | Share |
|
PXSSustained Benefit Following 18 Month Bronchitol Treatment |
17/05/10 | PRICE SENSITIVE | | Share |
|
PXSAppendix 3B - Exercise of Employee Options |
30/04/10 | | | Share |
|
PXSPharmaxis resubmission for Aridol US marketing application |
27/04/10 | | | Share |
|
PXSAppendix 3B - Exercise of Employee Options |
23/04/10 | | | Share |
|
PXSChange in substantial holding |
22/04/10 | | | Share |
|
PXSAppendix 4C - quarterly March 2010 |
14/04/10 | PRICE SENSITIVE | | Share |
|
PXSMarch 2010 Quarterly Report to Shareholders |
14/04/10 | | | Share |
|
PXSPharmaxis Announces Milestone in Phase 3 Trial for CF |
14/04/10 | PRICE SENSITIVE | | Share |
|
PXSPHARMAXIS QUARTERLY INVESTOR CONFERENCE CALL |
12/04/10 | | | Share |
|
PXSAppendix 3B - Exercise of Employee Options |
23/03/10 | | | Share |
|
PXSDisclosure notice under section 708A(5)(e) |
15/03/10 | | | Share |
|
PXSAppendix 3B - Topigen Milestone Payment |
15/03/10 | | | Share |
|
PXSPharmaxis Completes Phase II Clinical Study with ASM8 |
11/03/10 | PRICE SENSITIVE | | Share |
|
PXSChange in substantial holding |
10/03/10 | | | Share |
|
PXSInvestor Presentation |
02/03/10 | | | Share |
|
PXSDisclosure notice under section 708A(5) of Corporations Act |
09/02/10 | | | Share |
|
PXSAppendix 3B - Topigen Acquisition |
09/02/10 | | | Share |
|
PXSPharmaxis completes acquisition of Topigen Pharmaceuticals |
09/02/10 | | | Share |
|
PXSPharmaxis completes clinical trial with PXS25 |
09/02/10 | PRICE SENSITIVE | | Share |
|
PXSAppendix 3B - Exercise of Employee Options |
05/02/10 | | | Share |
|
PXSHalf Yearly Report and Accounts |
05/02/10 | PRICE SENSITIVE | | Share |
|
PXSUpdated Investor Presentation |
28/01/10 | | | Share |
|
PXSAppendix 4C - Quarterly Cash Flow |
27/01/10 | PRICE SENSITIVE | | Share |
|
PXSDecember 2009 Quarterly Report to Shareholders |
27/01/10 | | | Share |
|
PXSInvestor Conference Call |
22/01/10 | | | Share |
|
PXSPharmaxis to acquire Canadian company TOPIGEN Pharmaceutical |
12/01/10 | PRICE SENSITIVE | | Share |
|
PXSPharmaxis receives response letter from the FDA on Aridol |
29/12/09 | PRICE SENSITIVE | | Share |
|
PXSPharmaxis lodges TGA application to market Bronchitol for CF |
17/12/09 | PRICE SENSITIVE | | Share |
|
PXSExercise of Employee Options |
09/12/09 | | | Share |
|
PXSChange of Director's Interest Notice |
08/12/09 | | | Share |
|
PXSChange in substantial holding |
03/12/09 | | | Share |
|
PXSPHARMAXIS ANNOUNCES SUSTAINED BENEFIT WITH BRONCHITOL |
02/12/09 | PRICE SENSITIVE | | Share |
|
PXSChange of Director's Interest Notice - Appendix 3Y |
26/11/09 | | | Share |
|
PXSAppendix 3B - Exercise of Employee Options |
26/11/09 | | | Share |
|
PXSFDA Advisory Committee Recommends Approval of Aridol |
23/11/09 | | | Share |
|
PXSPharmaxis Applies to Market Bronchitol for CF in Europe |
29/10/09 | PRICE SENSITIVE | | Share |
|
PXSAppendix 3B - Exercise of Employee Options |
27/10/09 | | | Share |
|
PXSCommencement of Bronchiectasis Study and Aligning Strategy |
23/10/09 | PRICE SENSITIVE | | Share |
|
PXSAppendix 3Y - Mr Richard van den Broek |
22/10/09 | | | Share |
|
PXSAppendix 3Y - Dr Alan Robertson |
22/10/09 | | | Share |
|
PXSAppendix 3B |
22/10/09 | | | Share |
|
PXSFinal Director's Interest Notice |
22/10/09 | | | Share |